Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India
South Asian Journal of Cancer · 21.11.2026 · 1-7
DOI: 10.25259/sajc_9_2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift South Asian Journal of Cancer, online erschienen am 21.11.2026. Verfasst von Ashok Singhal und 17 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Objectives
Prostate cancer is the second most prevalent cancer among men and increasingly affects younger individuals. These younger patients display distinct clinical and pathological profiles, with unclear prognostic outcomes. This study retrospectively analyses prostate cancer cases in men aged ≤55 years treated at Tata Memorial Hospital to understand the disease's characteristics and outcomes in this age group. Material and Methods: From 2012–2021, electronic medical records identified patients aged ≤55 years diagnosed with metastatic prostate cancer. Clinical and treatment data were extracted for analysis.
Results
The cohort comprised 150 patients (median age: 52 years). Most cases (95%) were adenocarcinoma, while 4% had neuroendocrine differentiation, and 1% presented pure small cell carcinoma. High-grade disease (Gleason 4–5) was common (87%), with 91% having prostate-specific antigen (PSA) levels >20 ng/mL. Bone metastases were predominant (91%), and 73% had high-volume disease. Treatment involved surgical castration (62%) or medical castration (38%). Initial therapies included docetaxel (52%), abiraterone (11%), or androgen deprivation therapy (ADT) alone (29%). ADT alone was more common before 2019, when combination therapies were less utilised. With a median follow-up of 61.4 months, the median overall survival (mOS) was 47.1 months, while survival post-castration resistance was 20.1 months. The mOS for ADT compared to ADT plus docetaxel or abiraterone was 44.8 vs. 59.2 months ( p = 0.062) in patients with low volume disease, and 37.7 versus 49.6 months ( p = 0.563) in patients with high volume disease. This lack of statistical significance may be attributed to the high proportion (28.4%) of high-volume disease patients who received ADT alone. Poor prognostic factors included neuroendocrine differentiation, Gleason 5, high disease volume, and visceral metastases.
Conclusion
Younger prostate cancer patients demonstrate more aggressive disease and worse outcomes compared to older cohorts. Prospective randomised trials are crucial to optimising management for this distinct population.
Zitieren
APA
Singhal, A., Tiwari, A., Jobanputra, K., Shah, M., Menon, N., Prakash, G., Arora, A., Pal, M., Murthy, V., Maitre, P., Menon, S., Thakkar, P. B., Katdare, A., Sable, N., Agrawal, A., Noronha, V., Prabhash, K., & Joshi, A. (2026). Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India. South Asian Journal of Cancer, 0, 1-7. https://doi.org/10.25259/sajc_9_2025
Vancouver
Singhal A, Tiwari A, Jobanputra K, Shah M, Menon N, Prakash G, et al. Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India. South Asian Journal of Cancer. 2026;0:1-7. doi:10.25259/sajc_9_2025
BibTeX
@article{Singhal2026,
author = {Singhal, Ashok and Tiwari, Atul and Jobanputra, Kunal and Shah, Minit and Menon, Nandini and Prakash, Gagan and Arora, Amandeep and Pal, Mahendra and Murthy, Vedang and Maitre, Priyamvada and Menon, Santosh and Thakkar, Palak Bhavesh and Katdare, Aparna and Sable, Nilesh and Agrawal, Archi and Noronha, Vanita and Prabhash, Kumar and Joshi, Amit},
title = {Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India},
journal = {South Asian Journal of Cancer},
year = {2026},
volume = {0},
pages = {1--7},
doi = {10.25259/sajc_9_2025}
}
EUVIMED